Fatehi Elnour Elzein - Infectious Diseases

Author Information

Fatehi Elnour Elzein is a prominent researcher in the field of Infectious Diseases. He is affiliated with the Infectious Diseases Unit at Prince Sultan Military Medical City (PSMMC) in Riyadh, Saudi Arabia. His research primarily focuses on infectious diseases, including Middle East Respiratory Syndrome (MERS), COVID-19, and other bacterial and fungal infections prevalent in the region.

Research Contributions

Fatehi Elnour Elzein has made significant contributions to the field of infectious diseases. His work includes studies on the antibody responses to Middle East Respiratory Syndrome Coronavirus, the efficacy of treatments for severe COVID-19, and various other bacterial and fungal infections. Notably, he has conducted research on the use of interferon and lopinavir/ritonavir in treating MERS and has explored the complexities of coinfections and the recurrence of diseases such as COVID-19 and brucellosis. His research is crucial in advancing the understanding and treatment of infectious diseases in the Middle East and globally.

Aliases

Fatehi Elnour Elzein is also known by various aliases, including F. Elzein, Fatehi E. Elzein, Fatehi E Elzein, and F Elzein. These variations may appear in different publications and databases.

Publication and Citation Metrics

Metric	Value
Total Papers	45
Total Citations	1419
H-index	11

Publications:

Longevity of Middle East Respiratory Syndrome Coronavirus Antibody Responses in Humans, Saudi Arabia

DOI: 10.3201/eid2705.204056

Year: 2021

Reinfection, recurrence, or delayed presentation of COVID-19? Case series and review of the literature

DOI: 10.1016/j.jiph.2021.01.002

Year: 2021

Brucella cardiac implantable electronic device infection: A single-center case series

DOI: 10.1016/j.amsu.2021.102568

Year: 2021

Efficacy of tocilizumab in patients with severe COVID-19: Survival and clinical outcomes

DOI: 10.1016/j.jiph.2021.05.015

Year: 2021

Abdominal tuberculosis in a tertiary care centre in Saudi Arabia.

DOI: 10.1016/J.IJTB.2020.09.007

Year: 2021

Complication of massive trauma by fungal infection and bone tuberculosis

DOI: 10.1016/j.mmcr.2019.12.006

Year: 2020

Interferon Beta-1b and Lopinavir-Ritonavir for Middle East Respiratory Syndrome.

DOI: 10.1056/NEJMoa2015294

Year: 2020

COVID-19 co-infection in a patient with brucella bacteremia

DOI: 10.1016/j.rmcr.2020.101183

Year: 2020

Treatment of Middle East respiratory syndrome with a combination of lopinavir/ritonavir and interferon-β1b (MIRACLE trial): statistical analysis plan for a recursive two-stage group sequential randomized controlled trial

DOI: 10.1186/s13063-019-3846-x

Year: 2020

Mucormycosis: An 8-year experience of a tertiary care centre in Saudi Arabia.

DOI: 10.1016/j.jiph.2020.08.002

Year: 2020

What is the Treatment for E. Coli Infection?

How Does the CDC Respond to Emerging Infectious Diseases?

How Can Herpes Be Prevented?

What is Immunodeficiency?

What precautions are necessary during air travel?

What is COVID-19?

How do you handle food and water safety?

What are the Key Components of HTS?

Why are Drug Targets Important?

What Measures Can Reduce the Spread of Respiratory Droplets?

Partnered Content Networks

Relevant Topics